首页> 外文期刊>National Journal of Community Medicine >Evaluation of Coverage and Compliance of Mass Drug Administration Programme 2011 For Elimination of Lymphatic Filariasis in Nalgonda District of Andhra Pradesh, India
【24h】

Evaluation of Coverage and Compliance of Mass Drug Administration Programme 2011 For Elimination of Lymphatic Filariasis in Nalgonda District of Andhra Pradesh, India

机译:对印度安得拉邦纳尔贡达区消除淋巴丝虫病的《 2011年大规模药物管理计划》覆盖范围和合规性的评估

获取原文
       

摘要

Background and Objectives: Lymphatic Filariasis has been a major public health problem in India next only to malaria. Government of India during 2004 initiated Mass DrugAdministration (MDA) with annual single dose of DEC tablets to all the population living atthe risk of Filariasis. Mass Drug Administration of Diethyl Carbamazine (DEC) &Albendazole; (ALB) was undertaken in 16 districts of Andhra Pradesh on 9th, 10th and 11th December 2011. Present study aimed to evaluate coverage and compliance rate of Mass Drug Administration for lymphatic Filariasisin Nalgonda district of Andhra Pradesh. Methods: Community Based cross-section study was undertaken among four selected clusters of Nalgonda district as per National Vector Borne Disease Control Programme (NVBDCP) guidelines. Information pertaining to coverage and compliance of MDA was gathered from 120 families from 4 clusters by interview technique using structured questionnaire. Results: The average family size was 4.21 and majority of the respondents were males and of more than 15 years of age. The eligibility, coverage and compliance rates were 96.2%, 79.7% and 43.04% respectively. On the spot consumption of tablets was reported by only 22.9% respondents. Most common cause for non-compliance was fear of side effects (47.5%).I E C activity was reported to be seen by only 21.7% respondents. Conclusion: Improving the community compliance in DEC consumption is the major challenge. There is an urgent need for effective MDA strategy with emphasis on Advocacy, social mobilization and monitoring.
机译:背景与目的:淋巴丝虫病是仅次于疟疾的印度主要的公共卫生问题。印度政府于2004年启动了大规模药物管理局(MDA),每年向所有面临丝虫病风险的人群提供DEC片剂单剂量。二乙基卡巴马嗪(DEC)和阿苯达唑的药品管理局(ALB)于2011年12月9日,10日和11日在安得拉邦的16个地区进行。本研究旨在评估安得拉邦纳尔贡达地区淋巴丝虫病的药物管理覆盖率和依从率。方法:根据国家病媒传染病控制计划(NVBDCP)指南,在纳尔贡达(Nalgonda)地区的四个选定集群中进行了基于社区的横断面研究。使用结构化问卷,通过访谈技术从4个聚类的120个家庭中收集了有关MDA覆盖和合规性的信息。结果:平均家庭人数为4.21,大多数受访者是男性,年龄在15岁以上。合格率,覆盖率和合规率分别为96.2%,79.7%和43.04%。现场报告的片剂消费量仅为22.9%。导致不合规的最常见原因是担心出现副作用(47.5%)。据报道,只有21.7%的受访者看到了I C活动。结论:改善社区对DEC消费的依从性是主要挑战。迫切需要有效的MDA战略,重点是宣传,社会动员和监测。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号